BidaskClub cut shares of Collegium Pharmaceutical (NASDAQ:COLL) from a buy rating to a hold rating in a report issued on Friday.
Other research analysts have also issued reports about the stock. Piper Jaffray Companies set a $33.00 price target on shares of Collegium Pharmaceutical and gave the stock a buy rating in a research note on Monday, February 12th. Janney Montgomery Scott set a $26.00 price objective on shares of Collegium Pharmaceutical and gave the company a buy rating in a research report on Tuesday, February 6th. Zacks Investment Research downgraded shares of Collegium Pharmaceutical from a buy rating to a hold rating in a research report on Friday, February 2nd. Jefferies Group increased their price objective on shares of Collegium Pharmaceutical to $32.00 and gave the company a buy rating in a research report on Monday, February 12th. Finally, Needham & Company LLC increased their price objective on shares of Collegium Pharmaceutical from $25.00 to $28.00 and gave the company a buy rating in a research report on Tuesday, December 5th. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. The company currently has an average rating of Buy and a consensus price target of $27.17.
Shares of Collegium Pharmaceutical (NASDAQ:COLL) traded up $0.59 during trading on Friday, hitting $24.50. 400,763 shares of the company traded hands, compared to its average volume of 567,983. The company has a market cap of $778.56, a price-to-earnings ratio of -8.22 and a beta of 0.80. Collegium Pharmaceutical has a 52 week low of $7.37 and a 52 week high of $26.77.
In related news, insider Alison B. Fleming sold 6,928 shares of the stock in a transaction dated Wednesday, January 10th. The shares were sold at an average price of $19.07, for a total transaction of $132,116.96. Following the sale, the insider now directly owns 32,651 shares of the company’s stock, valued at approximately $622,654.57. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Longitude Capital Partners, Ll sold 1,000,000 shares of the stock in a transaction dated Friday, December 8th. The shares were sold at an average price of $17.34, for a total transaction of $17,340,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 1,046,928 shares of company stock worth $18,422,317 over the last three months. 25.76% of the stock is currently owned by insiders.
A number of hedge funds have recently made changes to their positions in COLL. Citadel Advisors LLC grew its position in Collegium Pharmaceutical by 773.8% during the 3rd quarter. Citadel Advisors LLC now owns 544,033 shares of the specialty pharmaceutical company’s stock valued at $5,707,000 after purchasing an additional 481,771 shares during the last quarter. First Manhattan Co. purchased a new stake in shares of Collegium Pharmaceutical during the 4th quarter valued at about $8,606,000. Deutsche Bank AG boosted its holdings in shares of Collegium Pharmaceutical by 528.0% during the 4th quarter. Deutsche Bank AG now owns 414,115 shares of the specialty pharmaceutical company’s stock valued at $7,643,000 after acquiring an additional 348,169 shares during the last quarter. Cortina Asset Management LLC purchased a new stake in shares of Collegium Pharmaceutical during the 4th quarter valued at about $5,476,000. Finally, Macquarie Group Ltd. boosted its holdings in shares of Collegium Pharmaceutical by 21.5% during the 4th quarter. Macquarie Group Ltd. now owns 1,616,117 shares of the specialty pharmaceutical company’s stock valued at $29,833,000 after acquiring an additional 286,138 shares during the last quarter. 89.28% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: “Collegium Pharmaceutical (COLL) Stock Rating Lowered by BidaskClub” was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.thelincolnianonline.com/2018/02/24/collegium-pharmaceutical-coll-stock-rating-lowered-by-bidaskclub.html.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.